Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2007 1
2008 1
2009 2
2010 4
2011 4
2012 1
2013 1
2014 1
2015 1
2016 3
2018 1
2019 2
2020 10
2021 6
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

40 results
Results by year
Filters applied: . Clear all
Page 1
Chez les sujets avec insuffisance cardiaque à fraction d’éjection diminuée avec ou sans diabète de type 2, est-ce que la dapagliflozine, un inhibiteur des SGLT2, est efficace pour prévenir l’insuffisance cardiaque décompensée ou la mortalité cardiovasculaire tout en étant sécuritaire ?
Lanthier L, Dussault C, Huard G, Plourde MÉ, Cauchon M. Lanthier L, et al. Rev Med Interne. 2020 Feb;41(2):143-144. doi: 10.1016/j.revmed.2019.12.011. Epub 2020 Jan 9. Rev Med Interne. 2020. PMID: 31928796 French. No abstract available.
[For obese patients or for patients who are overweight and have an associated comorbidity, how safe and effective is semaglutide as compared with placebo as an adjunct to lifestyle intervention for reducing body weight and other related end points?].
Lanthier L, Langlois MF, Plourde MÉ, Cauchon M. Lanthier L, et al. Rev Med Interne. 2021 May;42(5):369-370. doi: 10.1016/j.revmed.2021.03.334. Epub 2021 Apr 8. Rev Med Interne. 2021. PMID: 33838950 French. No abstract available.
40 results